Small vesicles of size extending from 30-100nm which can be found in most of the eukaryotic fluids and enables an array of significant cellular purposes. While the discovery of exosomes was done more than 30 years ago, not until lately that the scientists have started to use it for therapeutic purposes.
The potential therapeutic options of stem cells have been known long time back, but it has only been recently known that exosomes play a vital role in cellular functioning of stem cells. Of late, exosomes have been in advance drive as an innovative approach for retrieving the stem cell therapeutic effects with no hazards and complications of administering them into patients. Many exosome companies are opening, with many new market entrants.
Companies Commercializing Exosome Technologies
Over past few years, the following business corporations have arisen as experts in exosome therapy which include:
Aegle Therapeutics – Aegle is the initial company that received FDA approval for the its extracellular vesicle therapy to enter the clinical trials on humans. The company uses extracellular vesicles derived from bone marrow- Mesenchymal stem cells for the treatment of severe dermatological disorders.
Kimera Labs – Kimera Labs is involved in the development of the amniotic treatments and pharmacological mark, exosome-based regenerative therapies with FDA registered tissue facility.
Anjarium Biosciences – The company engineer’s extracellular vesicles using a technology known a Hybridosome technology which acts as smart carriers of the therapy. This expertise permits diagnostic and therapeutic loads to be added into the lumen, along with variation of properties of the vesicle surface.
Exosome Sciences – Exosome Sciences is employing its advanced technology to discover exosome-based biomarkers for accurate diagnosis and monitoring of conditions such as Alzheimer’s, Chronic Traumatic Encephalopathy (CTE), and others.
Capricor Therapeutics – The company an entered into a global license agreement with Cedars-Sinai Medical Center for IP associated developmental work for exosomes originating from cardiosphere-derived cells (CDCs) for regenerative therapy.
Exosomics Siena SpA – The company has developed a liquid biopsy technology using exosome with the main purpose of non-invasive cancer diagnostic.
Codiak Biosciences – Codiak Biosciences’ technology take advantage of the exclusive exosomes properties which has can deliver to lipids, nucleic acids, small molecules and proteins to several cell types.
RoosterBio – RoosterBio collaborated with Exopharm on August 2017 on a Stem Cell Exomere Program, intended to convey high-grade therapeutic extracellular vesicles that is obtained from adult stem cells into medical practice.
Creative Medical Technologies Holdings – Creative Medical holds a patent that covers the practice of company’s AmnioStem as production device to develop exosomes for the generation of injured tissues in brain due to stroke.
Exopharm – Exopharm holds patented technology known as LEAP for the purification procedure to develop proprietary exomeres in huge quantity and reduced rate.
Exogenus Therapeutics – Exogenus Therapeutics also known as Exo-T is a biotechnology company in pre-clinical and clinical trials keen in developing exosome-based skin lesions therapy.
Lonza – In May 2017, the company acquired HansaBioMed Life Sciences, a provider of expertise and facilities for exosome study, and also capitalized in a Italian company named Exosomics involved in the development of next-generation sequencing-based cancer tests.
ReNeuron – A clinical stage company based in UK involved in the development of CTX neural stem cell line.
Exosome Diagnostics – The company launched its first original instrument for capturing the exoprotein and examine straight from any kind biofluid.
Evox Therapeutics – Evox is harnessing and manufacturing the usual transferring abilities of extracellular vesicles for the development of a completely new biotherapeutics class.
– Rikitha K Murthy,